News Sentiment

R2AR34 sentiment intelligence

Ultragenyx Pharmaceutical Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report RSS feed
Weighted score 48 Balanced news tone 8 relevant articles
Exchange SAO Brazil
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 17.08 Week of 3 Jul 2026
Weighted tone 48/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

70/100 classification confidence.

Company focus 8

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

+42.5% over one week, - over four weeks, trend inactive, and materially above fair value.

Latest direct headline Neutral

Ultragenyx: The Setrusumab Reset Creates A Cleaner Rare Disease Opportunity

Market Reaction

Price moving ahead of tone

57/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 70/100 classification
One-week reaction 42.5% Price confirming higher
Trend fit Trend inactive Weekly context
Fair value 28.8% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 2
Neutral 4
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 8
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
GlobeNewswire 2
PR Newswire 2
Seeking Alpha 1
Investing.com 1
parameter.io 1
StockInvest.us 1

Event Lens

What the news is about

Classified themes
Market update 3
Earnings 2
Regulatory and legal 2
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-8 of 8